Printer Friendly

COPLEY PHARMACEUTICAL ANNOUNCES FDA APPROVAL FOR MICONAZOLE NITRATE VAGINAL CREAM

 COPLEY PHARMACEUTICAL ANNOUNCES FDA APPROVAL
 FOR MICONAZOLE NITRATE VAGINAL CREAM
 CANTON, Mass., Nov. 5 /PRNewswire/ -- Copley Pharmaceutical, Incorporated (NASDAQ-NMS: CPLY) announced today that it has received approval from the Food and Drug Administration (FDA) for the company's Miconazole Nitrate vaginal cream.
 The company's product, which will be marketed as Miconazole Cream, is the generic equivalent of Monistat 7(R), the leading non-prescription brand used in the treatment of vaginal yeast infections. Monistat 7 is manufactured by Ortho Pharmaceutical Corporation.
 Miconazole Cream will be marketed through a manufacturing and distribution agreement with Perrigo Company, the nation's largest manufacturer of over-the-counter (non-prescription) pharmaceuticals and personal care products for the store brand market.
 Copley Pharmaceutical, Inc. develops and manufactures a broad range of off-patent prescription and over-the-counter pharmaceutical products. The company's product list includes a total of 81 dosage forms and strengths of 47 prescription and 13 over-the-counter drugs. Product categories include antihistamines, central nervous system agents, caloric and water balance products, skin and mucous membrane agents, and prescription vitamins.
 -0- 11/5/92
 /CONTACT: Dr. Mark Hirsh, vice president-marketing of Copley Pharmaceutical, 617-821-6111/
 (CPLY) CO: Copley Pharmaceutical, Incorporated ST: Massachusetts IN: MTC SU:


TS-CK -- NY040 -- 2970 11/05/92 10:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 5, 1992
Words:200
Previous Article:QUEENS SITE SELECTED FOR NEW YORK TIMES PLANT
Next Article:50-OFF STORES REPORTS SALES FOR OCTOBER AND THIRD QUARTER
Topics:


Related Articles
PERRIGO TO MARKET MICONAZOLE CREAM VIA A JOINT PRODUCT AGREEMENT WITH COPLEY PHARMACEUTICAL, INC.
A. L. LABORATORIES ANNOUNCES RECEIPT OF THREE NEW PRODUCT APPROVALS FROM FDA
PROCTER-SYNTEX ANNOUNCES CLEARANCE OF SECOND CONSUMER BRAND
PROCTER-SYNTEX ANNOUNCES NATIONWIDE AVAILABILITY OF 3-DAY OVER-THE-COUNTER FEMSTAT 3
Perrigo Receives FDA Tentative Approval For Children's Ibuprofen Oral Suspension
Copley Pharmaceutical Receives ANDA Approval for Hydrocortisone Valerate Cream USP, 0.2%
Alpharma U.S. Pharmaceuticals Division Receives First Approval for M-Zole 3 Combination Pack.
KV Receives FDA Approval for Gynazole-1(TM), a One Dose Treatment for Vaginal Yeast Infections.
Perrigo Dismissed from Miconazole Patent Litigation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters